Maira Melis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maira Melis has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Akbayan Token
City Clinical Hospital No. 1, Almaty 050006, Kazakhstan
2 shared publications - Almira Akparova
Faculty of Medicine and Healthcare, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan
2 shared publications - Gaukhar Kurmanova
Faculty of Medicine and Healthcare, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan
2 shared publications - Laura Alikulova
City Clinical Infectious Hospital, Al-Farabi Kazakh National University, Almaty 050030, Kazakhstan
2 shared publications - Moldir Zhunisbek
City Clinical Hospital No. 1, Almaty 050006, Kazakhstan
2 shared publications - Nazima Zarubekova
Faculty of Medicine and Healthcare, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan
2 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1135
Respiratory Bacterial Profiles and Antimicrobial Resistance Patterns in Hospitalized Patients with COPD and Pneumonia in Almaty, Kazakhstan
Background: Local antimicrobial resistance surveillance and stewardship require up-to-date information on bacterial isolates recovered from respiratory specimens and their antimicrobial susceptibility patterns. In Kazakhstan, contemporary microbiological surveillance remains limited, particularly for hospitalized patients with chronic obstructive pulmonary disease (COPD) and pneumonia. This study aimed to characterize the microbial profiles and antimicrobial susceptibility patterns in respiratory specimens from these patient groups in Almaty, Kazakhstan. Methods: This retrospective observational study included adult patients hospitalized at a tertiary referral center between January 2024 and December 2025. Respiratory specimens (sputum and bronchoalveolar lavage) underwent bacterial culture, species identification using MALDI-TOF MS, and antimicrobial susceptibility testing via EUCAST disk diffusion. Susceptibility was interpreted according to EUCAST categories (S, I, R). Group comparisons were performed using Pearson’s chi-square or Fisher’s exact test with Benjamini–Hochberg correction. Results: Among 713 patients (255 with COPD exacerbation and 458 with pneumonia), Streptococcus pyogenes was the most frequently isolated organism in both groups, followed by viridans group streptococci (VGS) and Streptococcus pneumoniae. Gram-negative isolates included most frequently Klebsiella pneumoniae, Klebsiella aerogenes, and Pseudomonas aeruginosa. After correction for multiple testing, bacterial distribution did not differ significantly between COPD and pneumonia. Streptococcal isolates demonstrated consistently high susceptibility to β-lactams, while susceptibility to macrolides, clindamycin, and doxycycline was lower. Gram-negative organisms demonstrated more variable resistance profiles. MDR phenotypes were observed among K. pneumoniae isolates in 3/18 (16.7%) COPD and 9/29 (31.0%) pneumonia cases, and among P. aeruginosa isolates in 2/9 (22.2%) COPD and 5/28 (17.9%) pneumonia cases, with no statistically significant between-group differences. Conclusions: No statistically significant differences in bacterial isolate distributions were detected between the COPD exacerbation and pneumonia groups after correction for multiple comparisons; however, equivalence between the groups cannot be inferred from these findings. High in vitro susceptibility to β-lactams among streptococcal isolates contrasted with heterogeneous antimicrobial resistance patterns and the presence of MDR/XDR phenotypes among Gram-negative isolates. These findings provide institution-specific microbiological data that may support antimicrobial stewardship and future surveillance efforts, while recognizing that bacterial isolation from respiratory specimens does not necessarily establish an etiological role in infection.
- 13 November 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1135
Open AccessRespiratory Bacterial Profiles and Antimicrobial Resistance Patterns in Hospitalized Patients with COPD and Pneumonia in Almaty, Kazakhstan
Background: Local antimicrobial resistance surveillance and stewardship require up-to-date information on bacterial isolates recovered from respiratory specimens and their antimicrobial susceptibility patterns. In Kazakhstan, contemporary microbiological surveillance remains limited, particularly for hospitalized patients with chronic obstructive pulmonary disease (COPD) and pneumonia. This study aimed to characterize the microbial profiles and antimicrobial susceptibility patterns in respiratory specimens from these patient groups in Almaty, Kazakhstan. Methods: This retrospective observational study included adult patients hospitalized at a tertiary referral center between January 2024 and December 2025. Respiratory specimens (sputum and bronchoalveolar lavage) underwent bacterial culture, species identification using MALDI-TOF MS, and antimicrobial susceptibility testing via EUCAST disk diffusion. Susceptibility was interpreted according to EUCAST categories (S, I, R). Group comparisons were performed using Pearson’s chi-square or Fisher’s exact test with Benjamini–Hochberg correction. Results: Among 713 patients (255 with COPD exacerbation and 458 with pneumonia), Streptococcus pyogenes was the most frequently isolated organism in both groups, followed by viridans group streptococci (VGS) and Streptococcus pneumoniae. Gram-negative isolates included most frequently Klebsiella pneumoniae, Klebsiella aerogenes, and Pseudomonas aeruginosa. After correction for multiple testing, bacterial distribution did not differ significantly between COPD and pneumonia. Streptococcal isolates demonstrated consistently high susceptibility to β-lactams, while susceptibility to macrolides, clindamycin, and doxycycline was lower. Gram-negative organisms demonstrated more variable resistance profiles. MDR phenotypes were observed among K. pneumoniae isolates in 3/18 (16.7%) COPD and 9/29 (31.0%) pneumonia cases, and among P. aeruginosa isolates in 2/9 (22.2%) COPD and 5/28 (17.9%) pneumonia cases, with no statistically significant between-group differences. Conclusions: No statistically significant differences in bacterial isolate distributions were detected between the COPD exacerbation and pneumonia groups after correction for multiple comparisons; however, equivalence between the groups cannot be inferred from these findings. High in vitro susceptibility to β-lactams among streptococcal isolates contrasted with heterogeneous antimicrobial resistance patterns and the presence of MDR/XDR phenotypes among Gram-negative isolates. These findings provide institution-specific microbiological data that may support antimicrobial stewardship and future surveillance efforts, while recognizing that bacterial isolation from respiratory specimens does not necessarily establish an etiological role in infection.
- Open Access
- 24 September 2026
- Published by MDPI AG in Preprints.org
Respiratory Bacterial Profiles and Antimicrobial Resistance Patterns in Hospitalized Patients with COPD and Pneumonia in Almaty, Kazakhstan
Background: Effective empirical therapy and antimicrobial stewardship rely on up-to-date local data on respiratory pathogens and antimicrobial resistance trends. In Kazakhstan, contemporary microbiological surveillance remains limited, particularly for hospitalized patients with chronic pulmonary disease (COPD) and pneumonia. This study aimed to characterize the microbial profiles and antimicrobial susceptibility patterns in respiratory specimens from these patient groups in Almaty, Kazakhstan. Methods: This retrospective observational study included adult patients hospitalized at a tertiary referral center between January 2024 and December 2025. Respiratory specimens (sputum and bronchoalveolar lavage) underwent bacterial culture, species identification using MALDI-TOF MS, and antimicrobial susceptibility testing via EU-CAST disk diffusion. Susceptibility was interpreted according to EUCAST categories (S, I, R). Group comparisons were performed using Pearson’s chi-square or Fisher’s exact test with Benjamini-Hochberg correction. Results: Among 713 patients (255 COPD exacerbation; 458 pneumonia), Streptococcus pyogenes was the most frequently isolated organism in both groups, followed by viridans group streptococci (VGS) and Streptococcus pneumoniae. Gram-negative isolates included most frequently Klebsiella pneumoniae, Klebsiella aerogenes, and Pseudomonas aeruginosa. After correction for multiple testing, bacterial distribution did not differ significantly between COPD and pneumonia. Streptococcal isolates demonstrated consistently high susceptibility to β-lactams, while susceptibility to macrolides, clindamycin, and doxycycline was lower. Gram-negative organisms demonstrated more variable resistance profiles. MDR phe-notypes were common among K. pneumoniae (16.7% COPD; 31.0% pneumonia) and P. aeruginosa (22.2% COPD; 17.9% pneumonia), with no significant between group dif-ferences. Conclusions: COPD exacerbation and pneumonia patients showed broadly similar bacterial profiles, whereas antimicrobial susceptibility varied substantially across species. High β-lactam activity against streptococci contrasted with complex resistance patterns and notable MDR/XDR phenotypes among Gram-negative organisms. These findings highlight the importance of ongoing institution-specific surveillance to support antimicrobial stewardship and guide empirical treatment decisions.
- 24 September 2026
- Published by MDPI AG in Preprints.org
Open AccessRespiratory Bacterial Profiles and Antimicrobial Resistance Patterns in Hospitalized Patients with COPD and Pneumonia in Almaty, Kazakhstan
Background: Effective empirical therapy and antimicrobial stewardship rely on up-to-date local data on respiratory pathogens and antimicrobial resistance trends. In Kazakhstan, contemporary microbiological surveillance remains limited, particularly for hospitalized patients with chronic pulmonary disease (COPD) and pneumonia. This study aimed to characterize the microbial profiles and antimicrobial susceptibility patterns in respiratory specimens from these patient groups in Almaty, Kazakhstan. Methods: This retrospective observational study included adult patients hospitalized at a tertiary referral center between January 2024 and December 2025. Respiratory specimens (sputum and bronchoalveolar lavage) underwent bacterial culture, species identification using MALDI-TOF MS, and antimicrobial susceptibility testing via EU-CAST disk diffusion. Susceptibility was interpreted according to EUCAST categories (S, I, R). Group comparisons were performed using Pearson’s chi-square or Fisher’s exact test with Benjamini-Hochberg correction. Results: Among 713 patients (255 COPD exacerbation; 458 pneumonia), Streptococcus pyogenes was the most frequently isolated organism in both groups, followed by viridans group streptococci (VGS) and Streptococcus pneumoniae. Gram-negative isolates included most frequently Klebsiella pneumoniae, Klebsiella aerogenes, and Pseudomonas aeruginosa. After correction for multiple testing, bacterial distribution did not differ significantly between COPD and pneumonia. Streptococcal isolates demonstrated consistently high susceptibility to β-lactams, while susceptibility to macrolides, clindamycin, and doxycycline was lower. Gram-negative organisms demonstrated more variable resistance profiles. MDR phe-notypes were common among K. pneumoniae (16.7% COPD; 31.0% pneumonia) and P. aeruginosa (22.2% COPD; 17.9% pneumonia), with no significant between group dif-ferences. Conclusions: COPD exacerbation and pneumonia patients showed broadly similar bacterial profiles, whereas antimicrobial susceptibility varied substantially across species. High β-lactam activity against streptococci contrasted with complex resistance patterns and notable MDR/XDR phenotypes among Gram-negative organisms. These findings highlight the importance of ongoing institution-specific surveillance to support antimicrobial stewardship and guide empirical treatment decisions.
- Open Access
- 26 August 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1893335
Multisystem inflammatory syndrome in adults (MIS-A): cardiovascular manifestations and in-hospital outcomes from two tertiary centers
Background: Multisystem inflammatory syndrome in adults (MIS-A) is a rare, post-infectious hyperinflammatory condition characterized by multiorgan involvement and substantial cardiovascular morbidity. This study aimed to characterize the cardiovascular phenotype and clinical outcomes of adults with MIS-A and to compare findings between ICU and non-ICU patients. Methods: We conducted a multicenter retrospective case series of 22 hospitalized patients with a MIS-A phenotype across two university-affiliated clinical bases in Almaty, Kazakhstan (City Hospital No. 1 and City Hospital No. 7). Data were retrospectively abstracted from completed inpatient medical records after discharge or in-hospital death. Demographics, clinical manifestations documented during hospital days 0−3, baseline laboratory markers (first 24 h), treatments, and outcomes were extracted from medical records. Results: The median age was 43 years (IQR, 29−63; range 19−86), and 13/22 patients were female (59.1%). Fever (≥38 °C) was documented on 18/22 (81.8%). Mucocutaneous findings included rash in 12/22 (54.5%), enanthema in 10/22 (45.5%), and non-purulent conjunctivitis in 5/22 (22.7%). Echocardiography was available for 17/22 (77.3%); LVEF <50% was observed in 6/17 (35.3%). Gastrointestinal symptoms occurred in 7/22 (31.8%), neurologic manifestations in 8/22 (36.4%), and respiratory manifestations in 16/22 (72.7%). Inflammatory markers were markedly elevated, including C-reactive protein (median 181 mg/L, IQR, 95.4–245.0) and D-dimer (median 6.4 µg/mL FEU, IQR, 4.0–10.0). Leukocytosis occurred in 15/22 (68.2%), thrombocytopenia in 11/22 (50.0%), and lymphopenia in 8/22 (36.4%). Systemic corticosteroids were used on 14/22 (63.6%); ICU admission occurred on 11/22 (50.0%). In-hospital mortality was 5/22 (22.7%). Conclusion: Hospitalized patients with a MIS-A phenotype demonstrated severe hyperinflammation with frequent multiorgan involvement and meaningful in-hospital mortality. Early recognition and standardized assessment of organ dysfunction, particularly cardiovascular involvement, are essential.
- 26 August 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1893335
Open AccessMultisystem inflammatory syndrome in adults (MIS-A): cardiovascular manifestations and in-hospital outcomes from two tertiary centers
Background: Multisystem inflammatory syndrome in adults (MIS-A) is a rare, post-infectious hyperinflammatory condition characterized by multiorgan involvement and substantial cardiovascular morbidity. This study aimed to characterize the cardiovascular phenotype and clinical outcomes of adults with MIS-A and to compare findings between ICU and non-ICU patients. Methods: We conducted a multicenter retrospective case series of 22 hospitalized patients with a MIS-A phenotype across two university-affiliated clinical bases in Almaty, Kazakhstan (City Hospital No. 1 and City Hospital No. 7). Data were retrospectively abstracted from completed inpatient medical records after discharge or in-hospital death. Demographics, clinical manifestations documented during hospital days 0−3, baseline laboratory markers (first 24 h), treatments, and outcomes were extracted from medical records. Results: The median age was 43 years (IQR, 29−63; range 19−86), and 13/22 patients were female (59.1%). Fever (≥38 °C) was documented on 18/22 (81.8%). Mucocutaneous findings included rash in 12/22 (54.5%), enanthema in 10/22 (45.5%), and non-purulent conjunctivitis in 5/22 (22.7%). Echocardiography was available for 17/22 (77.3%); LVEF <50% was observed in 6/17 (35.3%). Gastrointestinal symptoms occurred in 7/22 (31.8%), neurologic manifestations in 8/22 (36.4%), and respiratory manifestations in 16/22 (72.7%). Inflammatory markers were markedly elevated, including C-reactive protein (median 181 mg/L, IQR, 95.4–245.0) and D-dimer (median 6.4 µg/mL FEU, IQR, 4.0–10.0). Leukocytosis occurred in 15/22 (68.2%), thrombocytopenia in 11/22 (50.0%), and lymphopenia in 8/22 (36.4%). Systemic corticosteroids were used on 14/22 (63.6%); ICU admission occurred on 11/22 (50.0%). In-hospital mortality was 5/22 (22.7%). Conclusion: Hospitalized patients with a MIS-A phenotype demonstrated severe hyperinflammation with frequent multiorgan involvement and meaningful in-hospital mortality. Early recognition and standardized assessment of organ dysfunction, particularly cardiovascular involvement, are essential.
- Open Access
- 20 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 3126
Clinical Outcomes and Complications of Endoscopic Biliary Stenting for Malignant Distal Biliary Obstruction in Pancreatic Cancer: A Systematic Review
Background/Objectives: Malignant distal biliary obstruction (MDBO) is a frequent complication of pancreatic cancer and often leads to obstructive jaundice, impaired liver function, and delayed oncologic treatment. Endoscopic biliary drainage using endoscopic retrograde cholangiopancreatography (ERCP) with stent placement is the standard minimally invasive approach for restoring biliary flow. However, clinical outcomes and complication rates vary across studies depending on stent design, placement technique, and patient characteristics. The aim of this systematic review was to evaluate the clinical outcomes and complications associated with endoscopic biliary stenting in pancreatic cancer-related MDBO. Methods: A systematic literature search was performed in PubMed/MEDLINE, ScienceDirect, Web of Science, and the Cochrane Library for studies published between January 2016 and January 2026. Studies evaluating ERCP-guided biliary stenting in adult patients with pancreatic cancer-related malignant distal biliary obstruction were included. Study selection followed PRISMA 2020 guidelines, and methodological quality was assessed using the Newcastle–Ottawa Scale. Clinical outcomes including technical success, clinical success, stent patency, recurrent biliary obstruction, and procedure-related complications were analyzed. Results: Eighteen studies involving a total of 3291 patients were included in the qualitative synthesis. Technical success rates were consistently high, reaching up to 100% in several studies, while clinical success rates generally exceeded 90%. Median time to recurrent biliary obstruction ranged from approximately 102 to 541 days depending on stent type and placement technique. Recurrent biliary obstruction was the most frequently reported complication, occurring in 30.7% of patients. Stent migration occurred in 14.9% of cases, while post-ERCP pancreatitis was reported in approximately 4.2% of patients. Several studies demonstrated longer patency with self-expandable metal stents compared with plastic stents. Conclusions: Endoscopic biliary stenting performed during ERCP is an effective and safe strategy for the management of malignant distal biliary obstruction in pancreatic cancer. Self-expandable metal stents provide more durable biliary drainage and reduce the need for repeat interventions. Nevertheless, recurrent biliary obstruction remains a common limitation, highlighting the need for further improvements in stent technology and optimized placement strategies.
- 20 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 3126
Open AccessClinical Outcomes and Complications of Endoscopic Biliary Stenting for Malignant Distal Biliary Obstruction in Pancreatic Cancer: A Systematic Review
Background/Objectives: Malignant distal biliary obstruction (MDBO) is a frequent complication of pancreatic cancer and often leads to obstructive jaundice, impaired liver function, and delayed oncologic treatment. Endoscopic biliary drainage using endoscopic retrograde cholangiopancreatography (ERCP) with stent placement is the standard minimally invasive approach for restoring biliary flow. However, clinical outcomes and complication rates vary across studies depending on stent design, placement technique, and patient characteristics. The aim of this systematic review was to evaluate the clinical outcomes and complications associated with endoscopic biliary stenting in pancreatic cancer-related MDBO. Methods: A systematic literature search was performed in PubMed/MEDLINE, ScienceDirect, Web of Science, and the Cochrane Library for studies published between January 2016 and January 2026. Studies evaluating ERCP-guided biliary stenting in adult patients with pancreatic cancer-related malignant distal biliary obstruction were included. Study selection followed PRISMA 2020 guidelines, and methodological quality was assessed using the Newcastle–Ottawa Scale. Clinical outcomes including technical success, clinical success, stent patency, recurrent biliary obstruction, and procedure-related complications were analyzed. Results: Eighteen studies involving a total of 3291 patients were included in the qualitative synthesis. Technical success rates were consistently high, reaching up to 100% in several studies, while clinical success rates generally exceeded 90%. Median time to recurrent biliary obstruction ranged from approximately 102 to 541 days depending on stent type and placement technique. Recurrent biliary obstruction was the most frequently reported complication, occurring in 30.7% of patients. Stent migration occurred in 14.9% of cases, while post-ERCP pancreatitis was reported in approximately 4.2% of patients. Several studies demonstrated longer patency with self-expandable metal stents compared with plastic stents. Conclusions: Endoscopic biliary stenting performed during ERCP is an effective and safe strategy for the management of malignant distal biliary obstruction in pancreatic cancer. Self-expandable metal stents provide more durable biliary drainage and reduce the need for repeat interventions. Nevertheless, recurrent biliary obstruction remains a common limitation, highlighting the need for further improvements in stent technology and optimized placement strategies.